RSS Feeds

FibroGen to Present at the Goldman Sachs 38th Annual Global Healthcare Conference

SAN FRANCISCO, June 13, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that Chief Executive Officer Thomas B. Neff will participate in a Fireside Chat at the Goldman Sachs 38th Annual Global Healthcare Conference in Rancho Palos Verdes, California, on Thursday, June 15, at 10:40 a.m. Pacific Time. A live audio webcast of the presentation will be available under the Investors section of the FibroGen website at The replay of the webcast will be available for at least 14 days following the webcast.

About FibroGen, Inc.
FibroGen, Inc., headquartered in San Francisco, CA with subsidiary offices in Beijing and Shanghai, PRC, is a leading science-based biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD) and is entering Phase 3 development for anemia in lower risk myelodysplastic syndromes (MDS). Pamrevlumab, a fully-human monoclonal antibody that inhibits the activity of connective tissue growth factor (CTGF), is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more information, please visit

FibroGen, Inc.
Karen L. Bergman
Vice President, Investor Relations and Corporate Communications

Primary Logo

FibroGen, Inc.